Pembrolizumab is the standard for the first and second lines in treating metastatic urothelial
carcinoma (UC). This systematic review and meta-analysis aimed to assess the value of …

The management of advanced (locally advanced or metastatic) urothelial carcinoma has
been revolutionized since pembrolizumab was introduced in 2017. Several prognostic …

Background Reliable and affordable prognostic and predictive biomarkers for urothelial
carcinoma treated with immunotherapy may allow patients' outcome stratification and drive …

Neutrophil-to-lymphocyte ratio (NLR) was reported to be associated with prognosis of
urothelial cancer (UC) patients receiving systemic chemotherapy or immunotherapy …

Background/Aim: This study aimed to clarify the impact of proton pump inhibitors (PPIs) on
oncological outcomes in patients who received pembrolizumab for advanced urothelial …

Objectives To investigate the impact of the number of cycles and objective response to
chemotherapy on overall survival in patients with metastatic urothelial carcinoma treated …

Objectives To assess the impact of histological variants on survival and response to
treatment with pembrolizumab in patients with chemo‐resistant urothelial carcinoma (UC) …

Simple Summary Pembrolizumab, an immune checkpoint inhibitor, has shown therapeutic
benefit for advanced urothelial carcinoma (aUC) patients, but only a limited population …

Despite recent advancements in immunotherapy, urothelial carcinoma patients with liver
metastasis have a poor response to immune checkpoint inhibitors (ICIs) and short survival …

Background Chemoradiation therapy (CRT) has been increasingly reported as a possible
alternative to total cystectomy (TC) for localized bladder cancer (BC). Pembrolizumab is the …